NATIONWIDE PREVALENCE OF RA AND PENETRATION OF DMARDS IN SWEDEN Neovius M, Simard J & Askling J for the ARTIS Study Group Clinical Epidemiology Unit and.

Slides:

Advertisements

Similar presentations

The socio-economic burden of RMDs - What policies are needed to improve work capacity and avoid disability in the European Union? Ingemar Petersson, MD,

Advertisements

BSRBR-RA UK CRN ID: 7302 July 2014 update. Recruitment Certolizumab Must have diagnosis of RA Must be registered within 6 months of first dose of certolizumab.

Martin Neovius, PhDFinn Rasmussen, MD/PhD Dept of MedicineDept of Public Health Karolinska Institute Stockholm, Sweden Trends in and Consequences of Overweight.

EPIDEMIOLOGY. General How common is central sensitization/ dysfunctional pain? 17–35% of chronic pain patients suffer from generalized hypersensitivity.

EPIDEMIOLOGY. General Prevalence of Joint Pain Age-sex adjusted to the 2000 United States (US) standard population. Source: National Health Interview.

What is the definition of remission in RA? American Rheumatism Association (ARA)¹ Five or more of the following criteria must be fulfilled for at least.

Severe Hypoglycemia and Mortality After Cardiovascular Events for Type 1 Diabetic Patients in Sweden Featured Article: Tom W.C. Lung, Dennis Petrie, William.

Socialdepartementet Primary care and the care for the elderly.

Coverage & generalisability of the swedish biologics register ARTIS

Safety & Tolerability of Biologics Dubai, United Arab Emirates January 19th, 2009 Prof. Joachim R. Kalden Director emeritus Department of Internal Medicine.

1 Demographic and Clinical Characteristics of Rheumatoid Arthritis patients in some Arab States: Preliminary analysis Mohammed Hammoudeh,M.D Division of.

23 augusti 2015Veronica Vicente1 Track 8: Clinical Geriatrics Randomized Controlled Trial of a Prehospital Decision System by Emergency Medical Services.

Organizational Meeting for the AS-US Working Group Advancing Clinical Research in AS and SpA in the USA Spondylitis Association of America 20 Years of.

Musculoskeletal Health in Europe Health services utilisation.

Scandinavian Registers in Arthritis and Normal Populations Tuulikki Sokka, MD, PhD Jyväskylä Central Hospital, Jyväskylä, Finland.

1 Demographic and Clinical Characteristics of Rheumatoid Arthritis patients in some Arab States: Preliminary analysis Mohammed Hammoudeh Division of Rheumatology,

Nordic prescription registers Sweden Morten Andersen Professor Centre for Pharmacoepidemiology, Karolinska Institutet.

NSAIDs and Radiographic Progression in Ankylosing Spondylitis By Abd El-Samad El-Hewala Professor of Rheumatology and Rehabilitation Faculty of Medicine.

SICK LEAVE AND DISABILITY PENSION BEFORE AND AFTER INITIATION OF ANTIRHEUMATIC THERAPIES IN CLINICAL PRACTICE Neovius M, Simard JF, Klareskog L & Askling.

HOW LARGE ARE THE PRODUCTIVITY LOSSES IN CONTEMPORARY PATIENTS WITH RA AND HOW SOON IN RELATION TO DIAGNOSIS DO THEY DEVELOP? Neovius M, Simard JF & Askling.

1 Patient Safety In China Gao Xinqiang 23 June 2014.

Planning for Biosimilars: Infliximab Professor Ray Fitzpatrick Secondary Care lead Keele University Clinical Director of Pharmacy Royal Wolverhampton NHS.

Use of lung function tests in paediatric asthma care A nationwide registry study Grete Moth, MHSc, Ph.D Danish Paediatric Asthma Centre Aarhus University.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs : 2013 update Smolen.

Celiac Disease Increases Risk of Thyroid Disease in Patients With Type 1 Diabetes: A Nationwide Cohort Study Featured Article: Matthew Kurien, Kaziwe Mollazadegan,

Coexistence of BEonchiectasis and Rheumatoid Arthritis 장 나 은 Maria M Wilczynska MRCP, Alison M Condliffe PhD FRCP, and Damian J McKeon PhD FRCP.

The Clinical Practice Research Datalink Methodological Challenges in using Routine Clinical Data Dr Alison Nightingale, University of Bath.

Tumor necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis The Annals of the.

Antibiotic use and bacterial complications following upper respiratory tract infections: a population based study.

A NEW LOOK AT RA Interactive Hot Topics Series

The Management of Comorbid Conditions in Patients with Rheumatoid Arthritis Cardiovascular Risk.

From: Treatment of Very Early Rheumatoid Arthritis With Symptomatic Therapy, Disease-Modifying Antirheumatic Drugs, or Biologic AgentsA Cost-Effectiveness.

The Management of Comorbid Conditions in Patients with Rheumatoid Arthritis Depression Risk.

Recommendations for the treatment of established RA (disease duration 6 month or longer). Biologic, biological originator DMARD or boDMARD; DMARD, disease-modifying.

Prediction of Response to Targeted Treatment in Rheumatoid Arthritis

Nat. Rev. Rheumatol. doi: /nrrheum

Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on rheumatoid arthritis (RA) management. Algorithm based on the.

Awareness and Knowledge of Clinical Practice Guidelines for Systemic Lupus Erythematosus among Family Medicine Faculty and Residents Stephen James Kelton,

Figure 3 Simplified EULAR and GRAPPA

Figure 2 Simplified EULAR and GRAPPA

Mean change from baseline in disease and disability outcomes at 6 months for abatacept initiators by anti-CCP status. Mean change from baseline in disease.

ACR20, ACR50, and ACR70 response rates during the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. ACR20,

BeSt Study: Patient Characteristics Total Population Female 67% Male % Age (years) Duration of symptoms (weeks) 23 Time diagnosis.

Work arrangements, productivity, and self-confidence at work as affected by RA. a For example: Stopped working altogether, moved from full-time to part-time.

EULAR Study Group on Registers and Observational Drug Studies (RODS)

Association between anti-CCP antibody status and response to remission, LDA and mACR by anti-CCP status and TNFi initiators (multivariable models). Association.

Figure 1 Simplified EULAR and GRAPPA

Nat. Rev. Rheumatol. doi: /nrrheum

Infections and Biologic Therapy in Rheumatoid Arthritis

Updates in RA, PsA, and Biosimilars

Mean change from baseline CDAI in abatacept and TNFi initiators with a typical patient profile. Mean change from baseline CDAI in abatacept and TNFi initiators.

Mean change from baseline in disease and disability outcomes at 6 months for TNFi initiators by anti-CCP status. Mean change from baseline in disease and.

Workshop From petri dish to population - and back again

Additional efficacy outcomes for the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. Additional efficacy.

Different treatment strategies in rheumatoid arthritis in relation to radiographic progression (A) number of swollen joints (B) and fatigue severity over.

Column bar graphs showing Health Assessment Questionnaire (HAQ) scores and pain score on Visual Analogue Scale (VAS) (scale 0–10) that were collected at.

A. A. Change from baseline in Genant-modified Sharp total score. B. Erosion score. C. Joint-space narrowing score in patients originally randomized to.

Treatment strategy. Treatment strategy. For every patient, changes of treatment were analysed per change, for up to five subsequent therapeutic changes.

Clinical response in patients with early and established RA at month 24. *p

Clinical expertise of GPs and rheumatologists in differentiating patients with arthralgia. Clinical expertise of GPs and rheumatologists in differentiating.

Patients with RA on csDMARDs with and without GC, bDMARDs/tofacitinib with and without GC on the x axis. Patients with RA on csDMARDs with and without.

Step-down efficacy through week 48: categorical CDAI state DMARD-IR (RA-BEAM, RA-BUILD, RA-BEACON) analysis set. Step-down efficacy through week 48: categorical.

Efficacy in patients who received biologic and nonbiologic disease-modifying antirheumatic drugs in combination with rituximab. aLast-observation carried-forward.

Improvement in FACIT-F fatigue score according to ACR20 response status (ACR, American College of Rheumatology; DMARD, disease-modifying antirheumatic.

Percentage of patients achieving 20% improvement in the American College of Rheumatology criteria at week 12 by patient demographic and disease characteristics.

Malignancy-related events over time for all-bari-RA analysis set (IR).

All registries/studies are anti-TNF focused, excepting ORA (abatacept), AIR (rituximab), and RABBIT (anti-TNFs and anakinra). AIR = Autoimmunity and Rituximab;

Design for the long-term extension study RA-BEYOND from randomisation in the originating studies. Design for the long-term extension study RA-BEYOND from.

Incidence rates of hospitalised infection per 100 person-years, standardised for age and sex, among patients with RA from five RA registries and one RA.

Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on rheumatoid arthritis (RA) management. Algorithm based on the.

Presentation transcript:

NATIONWIDE PREVALENCE OF RA AND PENETRATION OF DMARDS IN SWEDEN Neovius M, Simard J & Askling J for the ARTIS Study Group Clinical Epidemiology Unit and Rheumatology Unit Dept of Medicine Karolinska Institutet Ann Rheum Dis, 2010

Objective To provide nationwide data on the prevalence of RA (including variations by age, sex, geography, demography and education level) and assess anti-rheumatic treatment penetration Neovius, Simard & Askling for the ARTIS Study Group, ARD 2010

Methods Patient Identification – Swedish Rheumatology Quality Register – National Patient Register (inpatient & specialist outpatient care) Treatment Exposure – Prescribed Drug Register – Swedish Biologics Register ARTIS Neovius, Simard & Askling for the ARTIS Study Group, ARD 2010

National Patient Register (NPR, ; n=57,400) Outpatient: n=48,644 Inpatient: n=32,777 Prescribed Drug Register (PDR, ; n=6,103) Swedish Rheumatology Quality Register (SRQ, ; n=18,201) ARTIS ( ; n=8,155) ARTIS & SRQ: n=8,155 ARTIS & PDR: n=5,750 ARTIS & NPR: n=7,965 PDR & SRQ: n=5,801 PDR & NPR: n=5,947 SRQ & NPR: n=17,499 Patient Identification Neovius, Simard & Askling for the ARTIS Study Group, ARD 2010

RESULTS

Cases defined as ever having a visit in inpatient or outpatient specialist care with a diagnosis of rheumatoid arthritis, or a listing in the Swedish Rheumatology Quality Register Prevalence of RA by Sex & Age Jan 1, 2008 (n=58,102) Neovius, Simard & Askling for the ARTIS Study Group, ARD 2010

Using Different Case Definitions Neovius, Simard & Askling for the ARTIS Study Group, ARD 2010

Using Different Case Definitions By Sex Neovius, Simard & Askling for the ARTIS Study Group, ARD 2010

Prevalence by Place of Residence Neovius, Simard & Askling for the ARTIS Study Group, ARD 2010

Prevalence by Place of Residence Neovius, Simard & Askling for the ARTIS Study Group, ARD 2010

Prevalence by Place of Residence Neovius, Simard & Askling for the ARTIS Study Group, ARD 2010

Prevalence by County (n=58,102) Neovius, Simard & Askling for the ARTIS Study Group, ARD 2010

No population statistics on education level for persons ≥75y 16-29y old persons excluded as many may not have completed their education Prevalence by Education Level and Age (n=39,551) Neovius, Simard & Askling for the ARTIS Study Group, ARD 2010

Comparison of prevalence estimates in the current study (Sweden 2008) with a previous Swedish study by Simonsson et al (Sweden 1995)[3], a Norwegian study by Kvien et al (Norway 1994)[2], and an American study by Gabriel et al (Rochester 1985)[7] after applying the age-cutoffs used in the respective studies Neovius, Simard & Askling for the ARTIS Study Group, ARD 2010

PENETRATION OF BIOLOGIC AND NON-BIOLOGIC DMARD S

Biologics Penetration by Age Neovius, Simard & Askling for the ARTIS Study Group, ARD 2010

Biologics Penetration by Age Neovius, Simard & Askling for the ARTIS Study Group, ARD 2010

DMARD Penetration by Age Non-Biologic Neovius, Simard & Askling for the ARTIS Study Group, ARD 2010

DMARD Penetration by Age Non-Biologic Neovius, Simard & Askling for the ARTIS Study Group, ARD 2010

References 1.Neovius M, Simard J, Askling J for the ARTIS Study Group Nationwide Prevalence of Rheumatoid Arthritis and Penetration of Disease-Modifying Drugs in Sweden Ann Rheum Dis Neovius M, Simard J, Sundström A, Jacobsson L, Geborek P, Saxne T, Klareskog L & Askling J for the ARTIS Study Group Generalisability of Clinical Registers used for Drug Safety and Comparative Effectiveness Research: Coverage of the Swedish Biologics Register Ann Rheum Dis Simard J, Arkema E, Sundström A, Geborek P, Saxne T, Baecklund E, Coster L, Dackhammar C, Jacobsson L, Rütting M, Lindblad S, Rantapää-Dahlqvist S, Klareskog L, Van Vollenhoven RF, Neovius M & Askling J Ten years with biologics: For whom do data on effectiveness and long-term safety apply? Rheumatology Askling J, Fored CM, Geborek P, Jacobsson LT, van Vollenhoven R, Feltelius N, Lindblad S & Klareskog L Swedish registers to examine drug safety and clinical issues in RA. Ann Rheum Dis 2006;65(6): Neovius M, Sundstrom A, Simard J, Wettermark B, Cars T, Feltelius N, Askling J & Klareskog L for the ARTIS Study Group Small-area variations in sales of TNF inhibitors in Sweden between 2000 and 2009 Scand J Rheumatol 2010